Menu
Innovation Observatory > Reports > Drugs > Tocilizumab (RoActemra) for Adults with Systemic Sclerosis – Second Line

< Back

Tocilizumab (RoActemra) for Adults with Systemic Sclerosis – Second Line

Drugs

Orthopaedics

December 2017


There is currently no cure for systemic sclerosis and treatment options focus on the management of symptoms. Tocilizumab is intended for the treatment of systemic sclerosis in adults. It is currently in development and early research indicates that it is able to target the key mechanisms thought to be responsible for the disease. If licensed, it could provide a new treatment option for adults with systemic sclerosis.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information

Tocilizumab for Systemic Sclerosis



Load More Related Posts
Get Alerts